Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007–2018

xlomafota13 shared this article with you from Inoreader Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007–2018 Via Melanoma Research - Published Ahead-of-Print Isolated limb perfusion (ILP) is widely accepted as treatment for recurrent melanoma limited to the limbs. The use of ILP has decreased in recent years with the introduction of potentially effective new systemic therapies. We evaluated retrospectively if ILP still may be a treatment option in locally advanced melanoma. In Finland, ILP is centralized to the Comprehensive Cancer Center of Helsinki University Hospital. We included all ILP patients treated at our hospital between 2007 and 2018. Clinical factors and treatment outcomes were retrospectively evaluated. Altogether 60 patients received ILP. Toxicity was mostly transient. The overall response rate was 77% with 35% complete responses and 42% partial responses. The median progression-free survival (PFS) was 6.1 months (range 0.6–116.5 months) and the median melanoma-specific survival (MSS) was 29.9 months (range 3.5–138.7 months). Patients with CR had superior median PFS (19.7 months, range 2.5–116.5 vs. 4.5 months, range 0.6–39.7 months, P = 0.00003) and median MSS (median MSS not reached vs. 25.9 months, range 3.5–98.7 months, P = 0.0005) compared to other responders. Younger patients ( View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.